Skip to main content
Equibles
SRPT logo

SRPT · Sarepta Therapeutics, Inc. · Metrics

Track SRPT — free

Use SRPT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SRPT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$19.00 +1.27 (+7.13%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.87B
Shares
105.63M
Volume · Oct 20 714.98K Avg daily vol (3M) 3.08M

SRPT metrics

88 of 116 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$17.73
Market cap
$1.87B

Price action

20 metrics
Price change (1W)
+1.7%
Price change (30D)
-12.0%
Price change (3M)
+5.3%
Price change (6M)
-17.2%
Price change (YTD)
-17.6%
Price change (1Y)
-21.2%
Trailing year
Price change (5Y)
-78.0%
52-week high
$24.45
52-week low
$14.86
Change from 52-week high
-27.5%
Change from 52-week low
+19.3%
Annualized volatility
79.4%
Annualized volatility (3M)
62.3%
Beta
2.1
RSI (14D)
46.4
Price vs SMA 50
-7.6%
Price vs SMA 200
-6.1%
Avg volume (3M)
3.08M
Relative volume
0.8
Average dollar volume
$56.98M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
105.63M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.9×
reciprocal yield 105.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.9×
reciprocal yield 109.3%
P / book
1.2
reciprocal yield 84.6%
FCF yield
4.5%
TTM · current market cap
Buyback yield
—
P / FCF
22.1
reciprocal yield 4.5%
P / operating cash flow
16.3
reciprocal yield 6.1%
Earnings yield
-7.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
4.3×
reciprocal yield 23.3%
EV / revenue historical average (5Y)
6.5×
reciprocal yield 15.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
233.0×
reciprocal yield 0.4%
EV / EBITDA historical average (5Y)
233.0×
reciprocal yield 0.4%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
98.8%
Operating margin
-7.3%
Trailing 12 months
Net margin
-6.9%
Gross profit (TTM)
$1.02B
Operating profit (TTM)
−$143.25M
Net income (TTM)
−$136.72M
Trailing 12 months
Diluted EPS (TTM)
$-1.60
FCF margin
4.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$18.39
Gross profit per diluted share (TTM)
$10.13
Operating profit per diluted share (TTM)
$-2.24
EBITDA per diluted share (TTM)
$-1.82
Net income per diluted share (TTM)
$-2.12
Operating cash flow per diluted share (TTM)
$1.42
Free cash flow per diluted share (TTM)
$1.14
Capital expenditures per diluted share (TTM)
$0.29
R&D per diluted share (TTM)
$7.69
Stock compensation per diluted share (TTM)
$0.93
Book value per share
$10.87

Growth

11 metrics
Revenue growth YoY
-34.3%
Year over year
Net income growth YoY
-102.5%
Revenue (TTM)
$1.97B
Trailing 12 months
EPS growth YoY
-102.6%
Shares change YoY
-1.1%
Year over year · fewer shares
Revenue CAGR (3Y)
+33.1%
Revenue CAGR (5Y)
+32.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-8.9%
Return on assets
-4.3%
Debt / equity
0.6
Current ratio
4.4
EBITDA (TTM)
−$98.54M
Free cash flow (TTM)
$81.85M
Quick ratio
2.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$59.13M
Latest balance sheet
Cash & equivalents
$571.15M
Total assets
$3.19B
Total debt
$847.62M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$111.01M
Capital expenditures (TTM)
$29.16M
R&D (TTM)
$789.44M
SG&A (TTM)
$436.74M
Stock compensation (TTM)
$98.81M
R&D / revenue
40.0%
Stock compensation / revenue
5.0%

Ownership (13F)

3 metrics
13F filers
331
13F filer change QoQ
-19
Institutional ownership
107.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
35.8%

Short interest

3 metrics
Short interest
21.6%
Latest settlement · 8.6 days to cover
Days to cover
8.6d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 873303 CUSIP 803607100 13F (30d) 27 filings 26 filers Visit website Investor relations